WO2014050717A1 - Agent d'amélioration de l'état de la peau - Google Patents

Agent d'amélioration de l'état de la peau Download PDF

Info

Publication number
WO2014050717A1
WO2014050717A1 PCT/JP2013/075418 JP2013075418W WO2014050717A1 WO 2014050717 A1 WO2014050717 A1 WO 2014050717A1 JP 2013075418 W JP2013075418 W JP 2013075418W WO 2014050717 A1 WO2014050717 A1 WO 2014050717A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin condition
substance
improving agent
skin
agent according
Prior art date
Application number
PCT/JP2013/075418
Other languages
English (en)
Japanese (ja)
Inventor
妙子 飯野
恵 岡田
孝子 今尾
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Priority to JP2014538450A priority Critical patent/JP6400474B2/ja
Priority to CN201380048868.2A priority patent/CN104661537A/zh
Publication of WO2014050717A1 publication Critical patent/WO2014050717A1/fr
Priority to HK15106870.5A priority patent/HK1206561A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an agent for improving the skin condition such as sagging, texture, firmness, and splinter lines.
  • An object of the present invention is to provide a composition in an easy-to-ingest form that can effectively improve the deterioration of the skin condition such as sagging, texture, firmness, or splinter that occurs with age. To do.
  • the present inventor has found that the skin condition can be effectively improved by combining specific substances.
  • the present invention relates to, but is not limited to: [1] An agent for improving skin condition, comprising at least one of the following substances together with 1) a collagen peptide, and 2) proteoglycan: 3) Blood circulation promoting substance, 4) antioxidants, 5) Estrogen-like substance. [2] The skin condition improving agent according to [1], comprising all of the substances 1) to 5). [3] [3] The skin condition improving agent according to [1] or [2], wherein the blood circulation promoting substance of 3) is a hihatsu extract. [4] 4. The skin condition improving agent according to any one of [1] to [3], wherein the antioxidant of 4) is vitamin C or a salt thereof, or a vitamin C derivative. [5] 5.
  • the skin condition improving agent according to any one of [1] to [4], wherein the estrogenic substance of 5) is flax lignan.
  • the skin condition improving agent according to any one of [1] to [5], wherein the collagen peptide of 1) has an average molecular weight of 300 to 10,000.
  • the skin condition-improving agent of the present invention can effectively improve the skin condition such as sagging, texture, firmness, or frying lines. As a result of improving skin sagging, it is expected that the face line can also be improved.
  • the skin condition improving agent of the present invention includes at least one selected from 1) collagen peptide and 2) proteoglycan, 3) blood circulation promoting substance, 4) antioxidant substance, and 5) estrogen-like substance.
  • the collagen peptide used in the skin condition improving agent of the present invention can be obtained by hydrolyzing denatured collagen such as collagen or gelatin with an enzyme, acid, alkali or the like, but its origin and production method are not limited at all. Not.
  • collagen or gelatin as a raw material may be derived from cows, pigs, chickens, fish, etc., and one or more of these can be used as raw materials.
  • Any enzyme can be used for collagen peptide preparation as long as it can cleave the peptide bond of collagen or gelatin.
  • collagenase, papain, bromelain, actinidine, ficin, cathepsin, pepsin, chymosin, trypsin, and these Examples thereof include enzyme preparations mixed with enzymes.
  • the acid for example, hydrochloric acid, sulfuric acid, nitric acid and the like can be used.
  • alkali examples include sodium hydroxide and calcium hydroxide.
  • an aqueous solution of a hydrolyzed collagen peptide may be used as it is, or a powdered powder by drying or the like may be used.
  • the average molecular weight of the collagen peptide is not particularly limited. However, the higher the average molecular weight, the lower the absorbability of the collagen peptide in the body, and the easier it is to solidify at low temperatures. The lower the average molecular weight, the more the absorbability in the body increases, but the bitterness, the bitterness, etc. peculiar to the peptide occur. Considering these points, the average molecular weight of the collagen peptide used in the present invention is preferably 300 to 10,000, more preferably 500 to 9,000, and particularly preferably 500 to 6,000.
  • the average molecular weight of the collagen peptide in this specification means a weight average molecular weight, and means a value measured by the Pagii method (gel filtration chromatography method).
  • collagen peptide a commercially available product may be used, and a collagen peptide having a preferable molecular weight can be used.
  • a collagen peptide having a preferable molecular weight can be used.
  • commercially available “Nippi Peptide PRA” Nippi Co., Ltd.
  • Water-soluble collagen peptide SS Water-soluble collagen peptide SS”
  • Collagen Peptide SCP Collagen Peptide SCP
  • HACP Zelais Co., Ltd.
  • Etc. a commercially available “Nippi Peptide PRA” (Nippi Co., Ltd.), “Water-soluble collagen peptide SS” (Kyowa Hakko Bio Co., Ltd.), “Collagen Peptide SCP” (Nitta Gelatin Co., Ltd.), “HACP” (Zelais Co., Ltd.) Etc.
  • one type of collagen peptide may be used alone, or two or more types of collagen peptides may be used in combination.
  • the total content of the collagen peptide in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 1.0 to 35 w / v%, preferably 2 0.0 to 20 w / v%.
  • Proteoglycan is a general term for compounds in which glycosaminoglycans (mucopolysaccharides) such as chondroitin sulfate and dermatan sulfate are covalently bound to a protein as a core. This is a substance that exists in connective tissues such as cartilage and skin of animals and is necessary for maintaining the structure of these tissues.
  • Proteoglycans include, for example, Aggrecan, Versican, Neurocan, Brevican, Decorin, Biglycan, Testican, Perlecan, Distroglycan ( And Dystroglycan), Agrin, and Clostrin.
  • the proteoglycan used in the present invention is not limited to its type, origin and production method.
  • any of the above proteoglycans may be used alone, or two or more of them may be used in combination.
  • aggrecan is preferable, and it can be used alone or in combination with other proteoglycans.
  • animals derived from proteoglycans are not limited, and those derived from animals such as mammals (cow, pigs, etc.), birds (chicken, etc.), fishes (shark, salmon, etc.), mollusks (squid, octopus, etc.) In addition, those derived from one or more animals can be used.
  • the production method may be any known method such as an extraction method using a solvent such as water, an acid (such as acetic acid), an alkali (such as sodium hydroxide or potassium hydroxide), or an alcohol.
  • a known method such as desalting or molecular weight fractionation may be used for purification.
  • the molecular weight of proteoglycans is usually tens of thousands to tens of millions.
  • the molecular weight of the proteoglycan used in the present invention is not particularly limited, but is preferably 100,000 to 2,000,000.
  • the total content of proteoglycan in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.001 to 0.05 w / v%, preferably 0.002 to 0.02 w / v%.
  • the content may be measured by any known method, for example, a gel chromatography molecular weight fractionation method can be used. That is, molecular weight fractionation is performed using gel chromatography, and quantification is performed using a proteoglycan standard reagent (proteoglycan, derived from salmon nasal cartilage (Wako Pure Chemical Industries)), or the molecular weight is 10,000 or more and the presence of acidic sugars and proteins Measure the dry matter of the fractions that have been confirmed. The presence of acidic sugar can be confirmed by the carbazole sulfate method, and the presence of protein can be confirmed by absorbance measurement at around 280 nm. *
  • blood circulation promoting substance refers to a substance that can promote blood flow in the body through expansion of peripheral blood vessels, suppression of platelet aggregation ability, maintenance of vascular endothelial function, and the like.
  • Blood circulation promoting substances are well known, and any of them may be used in the present invention, but examples include hihatsu extract, ginger extract, pine bark extract, hesperidin, and black pepper extract. Among them, the hihatsu extract is preferable.
  • Hihatsu extract can be obtained by concentrating the juice or extract obtained from the ears of Hihatsu (Long pepper, PiperP longum) by methods such as pressing or solvent extraction.
  • a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.
  • one kind of blood circulation promoting substance may be used alone, or two or more kinds of blood circulation promoting substances may be used in combination.
  • the total content of the blood circulation promoting substance in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.003 to 3 w / v%, preferably 0.1-1 w / v%.
  • Antioxidant refers to a substance that can suppress an oxidation reaction in a living body. Antioxidants are well known and any of them may be used in the present invention, but examples include vitamin E, vitamin A, carotenoids, vitamin B, flavonoids, polyphenols, glutathione, oligomeric pro Mention may be made of anthocyanidins, vitamin K, ⁇ -carotene, astaxanthin, vitamin C (ascorbic acid) or salts thereof, and vitamin C derivatives. Among these, vitamin C or a salt thereof, or a vitamin C acid derivative is preferable, and vitamin C or a salt thereof is more preferable.
  • Vitamin C derivatives are known and include all compounds that release vitamin C in vivo or in vitro and their solvates, hydrates and salts. Any vitamin C derivative may be used in the present invention, and examples include ascorbic acid glucoside, ascorbic acid phosphate, and salts and hydrates thereof.
  • Vitamin C or a salt thereof can be blended in the form of a cherry blossom extract or a lotus cup extract containing it.
  • the cherry blossom extract and the lotus cup extract are obtained by concentrating the juice and extract obtained from the cherry blossom and the fruit of the honeysuckle lotus cup (Lonicera caerulea L. ssp.edulis Hulten) by methods such as pressing and solvent extraction, respectively.
  • a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.
  • one kind of antioxidant substance may be used alone, or two or more kinds of antioxidant substances may be used in combination.
  • the total content of antioxidants in the skin condition improving agent of the present invention may vary depending on the use of the improving agent containing it, but is typically 0.01-2 w / v%, preferably 0.05-1 w / v%.
  • Estrogen-like substance refers to a substance having a physiological action similar to that of the female hormone estrogen. Estrogen-like substances are well known, and any of them may be used in the present invention, and examples include flax lignan, soybean isoflavone, isoxanthohumol, and 8-prenylnaringenin. Among these, flax lignan is preferable.
  • Flax lignan is a series of lignan compounds, such as secoisolariciresinol diglycoside (SDG), its metabolites enterodiol and enterolactone, matailesinol, pinoresinol, isolariciresinol, contained in flax seeds It is. Flax lignan is contained in the flaxseed extract, and the extract may be blended with the skin condition improving agent of the present invention.
  • the flaxseed extract can be obtained by concentrating the juice or extract obtained from flaxseed or flaxseed meal by a method such as pressing or solvent extraction. For extraction, a solvent such as water, methanol, ethanol, or isopropanol can be used. Further, although not essential, purification may be performed.
  • one estrogen-like substance may be used alone, or two or more kinds of estrogen-like substances may be used in combination.
  • the total content of the estrogen-like substance in the skin condition-improving agent of the present invention may vary depending on the use of the improving agent containing it. It is 0001 to 0.2 w / v%, preferably 0.001 to 0.1 w / v%.
  • the skin condition improving agent of the present invention may further contain an additional component as long as the effect of the present invention is not adversely affected.
  • additional component are, for example, antioxidants, pigments, preservatives, seasonings, sweeteners, acidulants, pH adjusters, stabilizers, emulsifiers, nutrient enhancers, fragrances, fruit juices.
  • each active ingredient can be used in combination with ingredients such as ceramide, hyaluronic acid, placenta, and CoQ10.
  • the skin condition improving agent of the present invention is preferably an oral composition, and its form is not particularly limited.
  • it can be provided in the form of tablets, granules, liquids, capsules, pills, powders, troches, gel foods, and cereals. These can be provided as food and drink. In particular, beverages are preferred. Alternatively, it may be a pharmaceutical composition.
  • the skin condition improving agent of the present invention can be packed in a container.
  • the form of the container is not limited at all, and examples include a bottle, a can, a plastic bottle, a paper pack, an aluminum pouch, a vinyl pouch, or a blow molded container.
  • Examples of preferred combinations in the present invention are 1) collagen peptide, 2) proteoglycan, 3) baboon extract, 4) vitamin C or a salt thereof, or vitamin C derivative, and 5) flax lignan, and component 4) is preferably Vitamin C or its salt.
  • the present invention provides a composition comprising at least one selected from 1) a collagen peptide and 2) proteoglycan, 3) a blood circulation promoting substance, 4) an antioxidant, and 5) an estrogen-like substance. It is used in the manufacture of a skin condition improving agent.
  • the present invention is a method for improving skin condition, which is used in combination with 1) a collagen peptide and 2) a proteoglycan, 3) a blood circulation promoting substance, 4) Administering a composition comprising an antioxidant and 5) at least one selected from estrogenic substances.
  • Administration subjects include mammals such as humans. Specific selection, blending amount, intake amount, and the like of each component in the use and method can be determined as appropriate based on the above description regarding the skin condition improving agent.
  • the numerical range represented by the upper limit value and the lower limit value in this specification that is, “lower limit value to upper limit value” includes the lower limit value and the upper limit value.
  • the range represented by “1-2” includes 1 and 2.
  • the beverage used for the test was prepared as follows.
  • Collagen nasal cartilage extract containing 20% collagen peptide (molecular weight 3,000), baboon extract, ascorbic acid, proteoglycan (molecular weight about 450,000), flaxseed extract containing 40% SDG, other sweeteners, acidulants, flavorings
  • a sample A (beverage 50 ml) containing the components shown in Table 1 was produced by adding an appropriate amount of the mixture and mixing according to a conventional method.
  • the test was an open test. The subject took sample A once a day for 8 weeks, and the skin was inspected before ingestion, at 2 weeks, 4 weeks, and 8 weeks before ingestion. Specifically, skin elasticity measurement, skin texture image analysis, and visual judgment by a beauty specialist were performed.
  • the return rate of the right cheek was measured using a cut meter MPA580 manufactured by Integral. This is related to skin firmness.
  • texture image analysis a replica of the right cheek was collected and the number of textures was measured using a texture analysis device ASA-03RXD manufactured by Asahi Biomed.
  • ASA-03RXD manufactured by Asahi Biomed.
  • a judge specialized in beauty performed a visual inspection of the sagittal line and sagging of the cheeks, and the determination result was evaluated based on a five-level score.
  • Table 2 shows changes in skin elasticity. Taking Sample A for 8 weeks increased the average return rate from 64.3 ⁇ 2.9% to 69.5 ⁇ 4.1%.
  • Table 3 shows the results of the texture image analysis. By ingesting sample A for 8 weeks, the number of textures increased from 1.34 ⁇ 0.45 / mm to 1.57 ⁇ 0.46 / mm, resulting in fine texture.
  • Table 4 shows the results of visual evaluation.
  • Table 5 shows the evaluation criteria related to the visual evaluation.
  • the skin condition improving agent of the present invention showed an excellent improvement effect on the skin condition.

Abstract

La présente invention a pour effet d'améliorer efficacement l'état d'une peau affaissée, dont la texture ou la fermeté s'est dégradée au fil du temps, ou caractérisée par un creusement des sillons nasolabiaux du fait de l'âge. A cette fin, la présente invention fait appel 1) à des peptides de collagène, 2) à des protéoglycanes et au moins à une substance choisie parmi 3) une substance favorisant l'irrigation sanguine, 4) une substance antioxydante et 5) une substance analogue aux œstrogènes.
PCT/JP2013/075418 2012-09-27 2013-09-20 Agent d'amélioration de l'état de la peau WO2014050717A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2014538450A JP6400474B2 (ja) 2012-09-27 2013-09-20 肌の状態の改善剤
CN201380048868.2A CN104661537A (zh) 2012-09-27 2013-09-20 皮肤状态改善剂
HK15106870.5A HK1206561A1 (en) 2012-09-27 2015-07-20 Skin condition amelioration agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012-214995 2012-09-27
JP2012214995 2012-09-27

Publications (1)

Publication Number Publication Date
WO2014050717A1 true WO2014050717A1 (fr) 2014-04-03

Family

ID=50388122

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2013/075418 WO2014050717A1 (fr) 2012-09-27 2013-09-20 Agent d'amélioration de l'état de la peau

Country Status (5)

Country Link
JP (1) JP6400474B2 (fr)
CN (1) CN104661537A (fr)
HK (1) HK1206561A1 (fr)
TW (1) TW201427610A (fr)
WO (1) WO2014050717A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216373A (ja) * 2015-05-14 2016-12-22 株式会社東洋新薬 血流改善剤
JP2017048151A (ja) * 2015-09-03 2017-03-09 地方独立行政法人青森県産業技術センター コラーゲンゲル収縮促進剤、抗糖化剤及び皮膚外用剤
WO2019155955A1 (fr) * 2018-02-09 2019-08-15 サントリーホールディングス株式会社 Composition liquide à usage oral contenant un peptide de collagène, et procédé d'amélioration du goût de cette composition
JP2020125319A (ja) * 2015-09-03 2020-08-20 地方独立行政法人青森県産業技術センター 抗糖化剤及び皮膚外用剤
CN113875993A (zh) * 2021-12-07 2022-01-04 北京中科生仪科技有限公司 一种抗皱保湿、改善皮肤弹性的组合物及其制备工艺

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663921B (zh) * 2017-10-03 2019-07-01 統一企業股份有限公司 複方食品

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335698A (ja) * 2002-05-20 2003-11-25 Maruha Corp 高尿酸血症治療又は予防用組成物
JP2006143671A (ja) * 2004-11-22 2006-06-08 Jc Community:Kk 経口用皮膚老化予防・改善剤。
JP2008179632A (ja) * 2006-12-29 2008-08-07 Fuji Chem Ind Co Ltd 抗酸化剤
JP2009518311A (ja) * 2005-12-02 2009-05-07 アーチャー・ダニエルズ・ミッドランド カンパニー リグナン抽出物及びリグナン抽出物を含有する組成物を得る製法
JP2010155787A (ja) * 2008-12-26 2010-07-15 Maruzen Pharmaceut Co Ltd 抗炎症剤、抗老化剤、抗肥満剤、及び育毛剤、並びに、化粧料、及び美容用飲食品
JP2011148726A (ja) * 2010-01-21 2011-08-04 Shiseido Co Ltd たるみ改善用美容セット並びにこれを使用する美容方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006290782A (ja) * 2005-04-08 2006-10-26 Tokiwa Yakuhin Kogyo Kk 抗浮腫組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003335698A (ja) * 2002-05-20 2003-11-25 Maruha Corp 高尿酸血症治療又は予防用組成物
JP2006143671A (ja) * 2004-11-22 2006-06-08 Jc Community:Kk 経口用皮膚老化予防・改善剤。
JP2009518311A (ja) * 2005-12-02 2009-05-07 アーチャー・ダニエルズ・ミッドランド カンパニー リグナン抽出物及びリグナン抽出物を含有する組成物を得る製法
JP2008179632A (ja) * 2006-12-29 2008-08-07 Fuji Chem Ind Co Ltd 抗酸化剤
JP2010155787A (ja) * 2008-12-26 2010-07-15 Maruzen Pharmaceut Co Ltd 抗炎症剤、抗老化剤、抗肥満剤、及び育毛剤、並びに、化粧料、及び美容用飲食品
JP2011148726A (ja) * 2010-01-21 2011-08-04 Shiseido Co Ltd たるみ改善用美容セット並びにこれを使用する美容方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016216373A (ja) * 2015-05-14 2016-12-22 株式会社東洋新薬 血流改善剤
JP2017048151A (ja) * 2015-09-03 2017-03-09 地方独立行政法人青森県産業技術センター コラーゲンゲル収縮促進剤、抗糖化剤及び皮膚外用剤
JP2020125319A (ja) * 2015-09-03 2020-08-20 地方独立行政法人青森県産業技術センター 抗糖化剤及び皮膚外用剤
WO2019155955A1 (fr) * 2018-02-09 2019-08-15 サントリーホールディングス株式会社 Composition liquide à usage oral contenant un peptide de collagène, et procédé d'amélioration du goût de cette composition
CN113875993A (zh) * 2021-12-07 2022-01-04 北京中科生仪科技有限公司 一种抗皱保湿、改善皮肤弹性的组合物及其制备工艺
CN113875993B (zh) * 2021-12-07 2022-04-01 北京中科生仪科技有限公司 一种抗皱保湿、改善皮肤弹性的组合物及其制备工艺

Also Published As

Publication number Publication date
TW201427610A (zh) 2014-07-16
CN104661537A (zh) 2015-05-27
JPWO2014050717A1 (ja) 2016-08-22
HK1206561A1 (en) 2016-01-15
JP6400474B2 (ja) 2018-10-03

Similar Documents

Publication Publication Date Title
JP6400474B2 (ja) 肌の状態の改善剤
JP5894341B2 (ja) コラーゲンペプチド、エラスチンペプチドおよびプロテオグリカンを含む組成物
JP6205616B2 (ja) 美肌促進剤及びその利用
JP6555886B2 (ja) コラーゲンペプチド含有水性液体組成物
CN106170213B (zh) 含有胶原蛋白肽组合物的苦味掩盖方法
JP2008239619A (ja) 末梢血行改善組成物
JP2014019660A (ja) 活性酸素抑制剤
JP6530187B2 (ja) コラーゲンペプチド含有組成物
WO2012157290A1 (fr) Agent prophylactique/thérapeutique pour la stéatose hépatique non alcoolique
JP2009161497A (ja) シソ抽出物、これを含む糖吸収阻害剤、ならびに、これらを用いた医薬品または医薬部外品、および食品または飲料
JP6608874B2 (ja) 美容組成物
JP2004346132A (ja) フラバン化合物含有組成物
JP2017165686A (ja) 肝機能改善剤
WO2005087758A1 (fr) Matière liée soluble dans l'eau à base de proanthocyanidine et composition contenant celle-ci
JP2015110526A (ja) 歯肉保護剤
JP7098198B2 (ja) 美容組成物
JP2018009038A (ja) 経口用組成物
JP6906248B2 (ja) 美容組成物
JP6211558B2 (ja) 美容組成物
JP6241631B2 (ja) 経口用組成物
JP6612064B2 (ja) 美容組成物
JP6452064B2 (ja) ヤナギタデスプラウト抽出物及びその製造方法、酵素活性阻害剤及び抗老化剤、並びに化粧料組成物及び機能性食品
JP6553849B2 (ja) 口臭抑制剤
JP6010482B2 (ja) 経口用組成物
JP2022089939A (ja) 肝機能改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13842685

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2014538450

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13842685

Country of ref document: EP

Kind code of ref document: A1